Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

pGALSc104(G217S) Citations (1)

Originally described in: Dominant gain-of-function mutations in Hsp104p reveal crucial roles for the middle region.
Schirmer EC, Homann OR, Kowal AS, Lindquist S Mol Biol Cell 2004 May;15(5):2061-72. Epub 2004 Feb 20.
PubMed Journal

Articles Citing pGALSc104(G217S)

KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells. Leiser D, Medova M, Mikami K, Nisa L, Stroka D, Blaukat A, Bladt F, Aebersold DM, Zimmer Y. Mol Oncol. 2015 Apr 14. pii: S1574-7891(15)00089-7. doi: 10.1016/j.molonc.2015.04.001. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.